CatalYm Publishes Data in Nature Communications Describing GDF-15 as a Central Factor of anti-PD-1 Resistance finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Oral presentation highlights first data from the GDFATHER-2a trial demonstrating lasting and confirmed responses (as per RECIST criteria) following treatment with visugromab and the anti-PD-1 inhibitor
CatalYm to Present Early Phase 2a Data on GDF-15 Neutralizing Antibody Visugromab at the 2023 ASCO Annual Meeting streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Oral presentation in "Developmental Therapeutics-Immunotherapy" session on Sunday, June 4 at 9:45 AM CDT CatalYm today announced that the first results from its ongoing Phase 2a trial "GDFATHER-2"
CatalYmtoday announced the close of a EUR 50 million (USD 49 million) Series C financing round. The oversubscribed round was co-led by new investors, Brandon Capital and Jeito Capital with participation